logo
Turbulence in the Oncology Workforce: A Silver Lining

Turbulence in the Oncology Workforce: A Silver Lining

Medscape19-06-2025
Physicians are in the midst of a tectonic shift in workforce patterns that could have ramifications lasting decades.
In a few short months, the current administration has implemented policies that will drastically reduce federal funding for academic science. These massive cuts include hundreds of terminated grants and slashed funding for 'indirect costs' for National Institutes of Health (NIH) research grant recipients. Alongside the federal budget cuts, entire divisions of the NIH and National Science Foundation are also being reorganized.
Clinicians at many academic institutions have been advised to prepare for uncertainty, while physicians and scientists have been instructed to restrict research hiring and spending, even terminate staff without existing grants or contracts. On top of that, entire global health programs have been decimated, and 'reduction in force' emails at the FDA, CDC, or Centers for Medicare and Medicaid Services have left many experts without a job.
However, amid this turbulence and confusion, there's a potential silver lining. The assaults on research funding and government programs may inadvertently help address a major issue: the physician shortage.
As many of my colleagues at academic institutions contemplate their next move, I suspect that oncologists may find themselves returning to full-time clinical practice and patient care.
And that may not be a bad thing.
Prior to the Trump administration's policies, the proportion of clinicians-hours spent seeing patients had declined nearly 8% over a decade. The number of doctors who spent most of their time seeing patients had dropped considerably as well. In fact, a 2024 survey from the American Medical Association found that over 35% of physicians expressed at least some interest in leaving clinical practice altogether. This, coupled with a massive influx of physicians entering retirement, is likely to exacerbate a growing physician shortage problem.
But what if more of us now choose to increase our time in the clinic or start practicing full time?
For many of my colleagues who cannot sustain a non-clinical career, I think that a return to full-time patient care will be a practical, even enticing move. And considering the shortages of physicians across almost all specialties, including oncology, doctors seeking refuge in clinical practice would be a welcome development.
Would I be content with a career that is increasingly more clinical? I think I would be. For me, clinical practice represents the ultimate refuge, the source of stability in a career that could otherwise be ruled by frequent career transitions encountered in the business world. The patient exam room is the one place where I can focus on a one-on-one relationship instead of the hustle and bustle of grant applications and administrative tasks.
Since patient care is often a health system's top revenue source, if more oncologists return to full-time practice, we may have more leverage to negotiate solutions that reduce burnout, advance practice providers, or provide greater vacation time. I also suspect that many clinicians who choose to spend more time with patients will do so as part of a medical group or private practice — potentially reversing a decades-long trend of doctors leaving private practice to work as employed physicians.
There are several tools that can help physicians make this transition easier. For one, the emergence of ambient artificial intelligence (AI) scribing may curb the exodus from clinical practice by reducing excessive documentation burdens. Instead of hyperbolic claims of AI 'replacing' physicians, I suspect that the AI revolution will simply provide physicians the necessary tools to be more efficient.
The growth of telemedicine and remote patient care platforms is another enabling factor. The rise of these virtual clinics means that physicians are no longer limited by geographically boundaries when practicing medicine. Continuing COVID-era policies that allow physicians to practice across state lines would also help.
If more physicians contemplate a return to their clinical roots, we have an opportunity to reshape the patient care experience in ways that both serve our communities and that create more sustainable clinical careers.
The physician workforce has always been adaptable. Now, if we can find our way back to the exam room, we will bring with us diverse experiences from research, policy, and business that can improve clinical practice.
Perhaps the silver lining in today's uncertainty is the chance to rediscover what drew us to medicine in the first place — the profound privilege of caring for patients — while leveraging our broader perspectives to address the systemic issues that drove many away in the first place. The future of healthcare may depend on our ability to transform this moment of professional disruption into one of renewal and recommitment to our core mission.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mizuho Raises Boston Scientific (BSX) Price Target as Robotics and Devices Drive Growth
Mizuho Raises Boston Scientific (BSX) Price Target as Robotics and Devices Drive Growth

Yahoo

time16 minutes ago

  • Yahoo

Mizuho Raises Boston Scientific (BSX) Price Target as Robotics and Devices Drive Growth

Boston Scientific Corporation (NYSE:BSX) ranks among the . Mizuho kept its Outperform rating on Boston Scientific Corporation (NYSE:BSX), and increased its price target for the medical device maker from $130 to $140 on July 24. The firm reported that the global recall of the ACURATE transcatheter aortic valve replacement (TAVR) system in the second half of the year was expected to be compensated by solid performance in Boston Scientific's FARAPULSE and WATCHMAN product lines. While Boston Scientific Corporation (NYSE:BSX) has no plans to re-engineer the ACURATE valve, putting it 'at square one in the TAVR space,' the company is still on track to acquire clearances for FARAPULSE in China and Japan before the end of the year, according to Mizuho's research. Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters. A leading name in robotics, the company has made great strides in the humanoid aspect of the industry with its two-legged Atlas robot. While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Was the potentially radioactive shrimp sold in your state? See map.
Was the potentially radioactive shrimp sold in your state? See map.

USA Today

time18 minutes ago

  • USA Today

Was the potentially radioactive shrimp sold in your state? See map.

A recall has been issued for frozen shrimp sold at Walmart in 13 states that may have been contaminated with a radioactive chemical, the Food and Drug Administration said. On Tuesday, Aug. 19, the FDA advised the recall after it detected Cesium-137 (Cs-137), a radioactive chemical "produced by nuclear fission for use in medical devices and gauges," according to the Environmental Protection Agency. The chemical was detected in four U.S. ports across the country and in a sample of breaded shrimp, the FDA stated. "Although testing to date has not confirmed the presence of contamination in any product in commerce, the product appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern," the FDA advised. The FDA is investigating the situation. Which states sold the recalled frozen shrimp? The recalled shrimp were sold in the following 13 states: More recalls: Over 78,000 Jeep Wrangler vehicles recalled. Here's why. Ports that received contaminated shipping containers The four ports where the FDA detected contaminated shipping containers are in the following cities: Which products were recalled? The recall is targeted at 2-pound bags of Great Value brand Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp. Lot codes and best by dates include the following: The shrimp products are processed by PT. Bahari Makmur Sejati, a company in Indonesia doing business as BMS Foods, according to the FDA. What to do if you have recalled shrimp If you have a package of the recalled Walmart shrimp at home, throw it away and do not eat or serve it, the FDA notice says. Distributors and retailers should dispose of the product and refrain from selling it. Anybody who fears they may have been exposed to elevated levels of cesium should contact their medical providers. To submit a complaint or report an adverse reaction, consumers can visit the FDA's Industry and Consumer Assistance portal. PT. Bahari Makmur Sejati placed under an import alert PT. Bahari Makmur Sejati has also been placed on an import alert for chemical contamination, which prevents any of the company's food products from entering the United States until it resolves any conditions that could have caused the exposure. The FDA is working with Indonesian seafood regulatory authorities to investigate the cause of the contamination. What is Cesium-137 (Cs-137) and why is it regulated? Cs-137 is a radioisotope of cesium, meaning it is a chemical element that emits radiation as it breaks down. It is man-made and is produced by nuclear fission, according to the FDA. In the United States, it is used in medical devices and measurement gauges, such as industrial devices that measure the thickness of materials. "It is also one of the byproducts of nuclear fission processes in nuclear reactors and nuclear weapons testing," the EPA stated. Because it is widespread around the globe, trace amounts can be found in the environment, including in soil, food and air, the FDA. Agencies, including the FDA and U.S. Customs & Border Protection, test for, monitor and regulate the presence of the substance due to the risks associated with long-term exposure. Low-level radiation exposure over time can lead to serious health complications, the FDA said. Exposure to Cs-137 alone can cause burns, acute radiation sickness, cancer and death. As a result, the governing agencies restrict potential exposure to lessen the possibility of these long-term impacts. Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram and TikTok: @juliamariegz, or email her at jgomez@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store